Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 5/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979459 | 1.00 | AR (0.42) | ARCYP19A1SCN9ATNIKESR1 | |
| SCHEMBL28914052 | 0.90 | SCN9A (0.50) | ARCYP19A1SCN9ATNIKESR1 | |
| SCHEMBL29978936 | 0.86 | NPC1 (0.44) | ARTNIKFAAHMAPK14 | |
| SCHEMBL23769408 | 0.86 | NPC1 (0.44) | ARTNIKFAAHMAPK14 | |
| SCHEMBL23769047 | 0.86 | AR (0.41) | ARSCN9ATNIKFAAHMAPK14 | |
| SCHEMBL25028531 | 0.80 | NPC1 (0.48) | FAAH | |
| SCHEMBL30895147 | 0.80 | NPC1 (0.48) | FAAH | |
| SCHEMBL23768824 | 0.79 | NPC1 (0.44) | ARSCN9ATNIKFAAHMAPK14 | |
| SCHEMBL29979274 | 0.79 | NPC1 (0.44) | ARSCN9ATNIKFAAHMAPK14 | |
| SCHEMBL25138346 | 0.79 | MAOA (0.46) | ARTNIKFAAHMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | claimed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | AR 4021/4885CYP19A1 4631/4885SCN9A 2284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.